Characteristics of patients with columnar-lined Barrett’s esophagus and risk factors for progression to esophageal adenocarcinoma

Table 1 Univariate analysis of potential risk factors for the development of esophageal adenocarcinoma in patients with columnar-lined esophagus

	Non-malignant	Malignant	P
	group (n = 553)	group (n = 44)
Age
<60 (yr: n, %)	189 (34.2)	13 (29.5)	0.532
>60 (yr: n, %)	364 (65.8)	31 (70.5)
Sex: male (%)	299 (54.1)	34 (77.3)	0.003
Smoking+: n (%)	161 (45.2)	21 (51.2)	0.466
Regular alcohol use±: n (%)	52 (15.2)	8 (20)	0.43
NSAIDs: n (%)	304 (55)	25 (56.8)	0.813
Specialized epithelium: n (%)	467 (84.4)	42 (95.5)	0.047
Length of CLE Median (cm)	5	6	0.001
Hiatul hernia: n (%)	314 (56.8)	22 (50)	0.383
Esophagitis: n (%)	330 (59.7)	13 (29.5)	<0.0001
Esophageal ulcer	117 (21.2)	11 (25)	0.55
Esophageal stricture	77 (13.9)	16 (36.4)	<0.0001
Hp in esophageal biopsy	42 (7.6)	2 (4.5)	0.456

CLE – columnar-lined esophagus; NSAIDs – non-steroidal anti-inflammatory drugs; Hp –Helicobacter pylori. +Information regarding smoking was available in only 356 patients of the non-malignant group and 41 patients of the malignant group; ^±information regarding alcohol consumption was available in only 342 patients of the non-malignant group and 40 patients of the malignant group.

Table 2 Risk factors associated with the development of adenocarcinoma in patients with CLE; results of multivariable regression analysis

Risk factors	Odds ratio	95%CI for Odds ratio	P
Age ≥60 yr	1.65	0.75–3.64	0.216
Male sex	5.12	2.04–12.84	0.0005
Regular alcohol use	1.15	0.46–2.90	0.76
NSAIDs	1.41	0.68–2.93	0.352
Esophagitis	0.28	0.13–0.57	0.0006
Esophageal stricture	4.37	2.02–9.45	0.0002

CLE – columnar lined esophagus; NSAIDs – non-steroidal anti-inflammatory drugs